References
- Saemundsson Y, Johansson C, Wenling S, et al. Hepatic venous Doppler in the evaluation of fetal extrasystoles. Ultrasound Obstet Gynecol. 2011;37(2):179–183.
- Naheed ZJ, Strasburger JF, Deal BJ, et al. Fetal tachycardia: mechanisms and predictors of hydrops fetalis. J Am Coll Cardiol. 1996;27(7):1736–1740.
- Miyoshi T, Maeno Y, Sago H, et al. Fetal bradyarrhythmia associated with congenital heart defects – nationwide survey in Japan. Circ J. 2015;79(4):854–861.
- Krapp M, Kohl T, Simpson JM, et al. Review of diagnosis, treatment, and outcome of fetal atrial flutter compared with supraventricular tachycardia. Heart. 2003;89(8):913–917.
- Ueda K, Maeno Y, Miyoshi T, et al.. The impact of intrauterine treatment on fetal tachycardia: a nationwide survey in Japan. J Matern Fetal Neonatal Med. 2018;31(19):2605–2610.
- Simpson JM, Maxwell D, Rosenthal E, et al. Fetal ventricular tachycardia secondary to long QT syndrome treated with maternal intravenous magnesium: case report and review of the literature. Ultrasound Obstet Gynecol. 2009;34(4):475–480.
- Jaeggi ET, Fouron JC, Silverman ED, et al. Transplacental fetal treatment improves the outcome of prenatally diagnosed complete atrioventricular block without structural heart disease. Circulation. 2004;110(12):1542–1548.
- Hofstaetter C, Hansmann M, Eik-Nes SH, et al. A cardiovascular profile score in the surveillance of fetal hydrops. J Matern Fetal Neonatal Med. 2006;19(7):407–413.
- Wieczorek A, Hernandez-Robles J, Ewing L, et al. Prediction of outcome of fetal congenital heart disease using a cardiovascular profile score. Ultrasound Obstet Gynecol. 2008;31(3):284–288.
- Neves AL, Mathias L, Wilhm M, et al. Evaluation of prenatal risk factors for prediction of outcome in right heart lesions: CVP score in fetal right heart defects. J Matern Fetal Neonatal Med. 2014;27(14):1431–1437.
- Miyoshi T, Katsuragi S, Neki R, et al. Cardiovascular profile score as a predictor of acute intrapartum non-reassuring fetal status in infants with congenital heart defects. J Matern Fetal Neonatal Med. 2017;30(23):2831–2837.
- Miyoshi T, Umekawa T, Hosoda H, et al. Plasma natriuretic peptide levels in fetuses with congenital heart defect and/or arrhythmia. Ultrasound Obstet Gynecol. 2018;52(5):609–616.
- Miyoshi T, Sakaguchi H, Shiraishi I, et al. Potential utility of pulsed-wave Doppler for prenatal diagnosis of fetal ventricular tachycardia secondary to long QT syndrome. Ultrasound Obstet Gynecol. 2018;51(5):697–699.
- Alsaied T, Baskar S, Fares M, et al. First-line antiarrhythmic transplacental treatment for fetal tachyarrhythmia: a systematic review and meta-analysis. J Am Heart Assoc. 2017;6(12):e007164.
- Miyoshi T, Maeno Y, Sago H, et al. Antenatal antiarrhythmic treatment for fetal tachyarrhythmias: a study protocol for a prospective multicentre trial. BMJ Open. 2017;7(8):e016597.
- Spinale FG, Tomita M, Zellner JL, et al. Collagen remodeling and changes in LV function during development and recovery from supraventricular tachycardia. Am J Physiol. 1991;261(2):H308–H318.
- Gopinathannair R, Etheridge SP, Marchlinski FE, et al. Arrhythmia-induced cardiomyopathies: mechanisms, recognition, and management. J Am Coll Cardiol. 2015;66(15):1714–1728.
- Donofrio MT, Moon-Grady AJ, Hornberger LK, et al. Diagnosis and treatment of fetal cardiac disease: a scientific statement from the American Heart Association. Circulation. 2014;129(21):2183–2242.
- Miyoshi T, Hosoda H, Umekawa T, et al. Amniotic fluid natriuretic peptide levels in fetuses with congenital heart defects or arrhythmias. Circ J. 2018;82(10):2619–2626.
- Miyoshi T, Hosoda H, Nakai M, et al. Maternal biomarkers for fetal heart failure in fetuses with congenital heart defects or arrhythmias. Am J Obstet Gynecol. 2019;220(1):104.e1–104.e15.